Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Crawford Strunk

Pediatric Hematology-Oncology Toledo, OH Medical Doctor

NPI 1770533291 CMS profile 171098

2142 N Cove Blvd, 5-South, Pediatrics, Toledo, OH 43606

Open in the dashboard

General payments

$51,779

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Crawford Strunk of Toledo, OH is reported in the CMS Open Payments database as having received $51,779 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,006 8
2024 General $269 6
2023 General $90 2
2022 General $17,861 18
2021 General $13,454 11
2020 General $5,631 8
2019 General $12,468 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Crawford Strunk
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Crawford Strunk were reported at $2,006. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Crawford Strunk Pediatric Hematology-Oncology median Middle half National median
2019 $12,468 $184 $69–$2,094 $163
2020 $5,631 $220 $37–$3,941 $114
2021 $13,454 $366 $63–$4,909 $132
2022 $17,861 $181 $66–$2,775 $149
2023 $90 $175 $62–$2,600 $160
2024 $269 $227 $66–$2,992 $164
2025 $2,006 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Global Blood Therapeutics, Inc. $20,427 22 payments
  2. Duchesnay USA Incorporated $15,438 4 payments
  3. Novartis Pharmaceuticals Corporation $12,965 15 payments
  4. Pfizer Inc. $1,647 3 payments
  5. Agios Pharmaceuticals, Inc. $554 11 payments
  6. Chiesi USA, Inc. $196 2 payments
  7. Emmaus Medical, Inc. $157 6 payments
  8. Amgen Inc. $153 2 payments
  9. Novo Nordisk Inc $122 1 payment
  10. Vertex Pharmaceuticals Incorporated $42 1 payment
  11. Other $78 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $27,125 9 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,905 9 payments
  3. Honoraria $8,695 6 payments
  4. Travel and Lodging $2,718 10 payments
  5. Food and Beverage $2,221 36 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,115 1 payment
Products named General payments · program years 2019–2025
  1. OXBRYTA Sickle Cell Disease $17,372 20 payments
  2. ADAKVEO $11,735 13 payments
  3. Siklos Sickle Cell Anemia $9,250 2 payments
  4. Siklos Sickle Cell Anemia $6,188 2 payments
  5. PYRUKYND $295 8 payments
  6. FERRIPROX $196 2 payments
  7. Endari $157 6 payments
  8. Blincyto $153 2 payments
  9. OXBRYTA Hematology $97 1 payment
  10. HEMLIBRA $24 1 payment
  11. Other $120 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

201

Median for Hematology-Oncology: 604

Drug cost

$145,099

Median for Hematology-Oncology: $1,306,514

Branded share of claims

48.8%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxbryta Voxelotor Brand 13 $141,049
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 30 $1,753
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 41 $1,112
Oxycodone Hcl Generic 69 $561
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $421
Gabapentin Generic 12 $69
Ibuprofen Generic 11 $67
Amitriptyline Hcl Generic 11 $66

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OXBRYTA
  • PFIZER INC. $97
$97 13 —
PYRUKYND
  • Agios Pharmaceuticals, Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Hematology-Oncology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record